Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives
- 1 December 2021
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 523, 162-169
Abstract
No abstract availableKeywords
This publication has 110 references indexed in Scilit:
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2012
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agentsProceedings of the National Academy of Sciences, 2012
- Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate CancerCancer Research, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based ChemotherapyCancer Research, 2010
- Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate CancerCancer Research, 2010
- Androgen receptor and growth factor signaling cross-talk in prostate cancer cellsEndocrine-Related Cancer, 2008
- Homologous recombination in DNA repair and DNA damage toleranceCell Research, 2008
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003